MYOM2 and Miyoshi myopathy: To thoroughly validate M-protein prognostic value, we analyzed progression-free survival (PFS) and overall survival (OS) in up to date the largest cohort of newly diagnosed MM patients (Supplementary Fig. 1a, b and Supplementary Table 1) and further, in a subgroup of patients who received bortezomib in the first line of therapy (Supplementary Fig. 1c, d and Supplementary Table 2).